M. V. Cunha
@mvcinvesting
Long-term investor. BSc in Economics, MSc in Finance. Equity Analyst with a focus on Fundamental Analysis and Valuation. Not a financial advisor.
Joined July 2020
403 Following 95.9K Followers
I'm far from a biotech expert, and I don't own $QURE (but I do have a small $CLPT position).
Am I the only one who thinks the 44% headline misses important context?
From what I've read, AMT-130 still seems to have a credible path to approval.
Curious to hear other views.
Show more
